Table 1.
Patient and tumor characteristics.
| Characteristics | N | % |
|---|---|---|
| All patients | 31 | 100.0 |
| Progressed | 25 | 80.6 |
| Alive | 18 | 58.0 |
| Age at baseline (years) | ||
| Median | 56 | |
| Range | 39–78 | |
| ER- and PR-receptor status | ||
| ER+ or PR+ | 21 | 68.0 |
| ER− and PR− | 10 | 32.0 |
| Her2/neu status | ||
| Positive | 3 | 10.0 |
| Negative | 28 | 90.0 |
| Triple negative | 8 | 26.0 |
| Sites of metastasis | ||
| Visceral | 21 | 68.0 |
| Non-visceral | 10 | 32.0 |
| Bone | 23 | 74.0 |
| Lung | 14 | 45.0 |
| Brain | 2 | 6.0 |
| Liver | 14 | 45.0 |
| Nodes | 19 | 61.0 |
| Number of metastasis | ||
| 1 | 9 | 29.0 |
| 2 or more | 22 | 71.0 |
| Therapy | ||
| First line | 11 | 35.5 |
| Second line or subsequent | 20 | 65 |
| Type of therapy | ||
| Chemotherapy alone | 20 | 64.5 |
| Chemotherapy and targeted therapy | 8 | 25.8 |
| Hormone-therapy | 2 | 6.5 |
| Placebo | 1 | 3.2 |